IL6 and melanoma: Targeting this cytokine-MDSC network with currently available therapies, such as those targeting the IL-6 receptor (tocilizumab) and IL-6 itself (siltuximab), or therapies that are undergoing clinical testing such as AZD5069, which targets IL-8, may provide new avenues to improve clinical outcomes for advanced melanoma patients.